Watanabe et al. described that VEGF‐A was highly expressed in mutant EGFR cells and that the EGFR signaling pathway can induce VEGFR2 pathway activation, suggesting the enhancement of antitumor effects of EGFR‐TKI through VEGFR2 inhibition.7 A recent clinical trial demonstrated that ramucirumab (a VEGFR2 inhibitor) plus erlotinib achieved superior progression‐free survival (PFS) compared with erlotinib alone in untreated EGFR‐mutated NSCLC.8 Here, KDR is linked to non-small cell lung carcinoma.